Choose Your Country or Region

Quetiapine (ICI-204636) fumarate

Name: Quetiapine (ICI-204636) fumarate
Brand: Selleck Chemicals
SKU: S1763
Rating: 5 (4 reviews)

Synonyms: ICI-204636 fumarate

Catalog No.S1763 Purity: 99.98%

Quetiapine Fumarate (ICI-204636) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression and shows affinity for various neurotransmitter receptors including serotonin, dopamine, histamine, and adrenergic receptors.

Quetiapine (ICI-204636) fumarate Chemical Structure

CAS: 111974-72-2

Selleck's Quetiapine (ICI-204636) fumarate has been cited by 4 publications

Purity & Quality Control

Batch: Purity: 99.98%

99.98

Quetiapine (ICI-204636) fumarate Related Products

Related Targets	D1 receptor D2 receptor D3 receptor D5 receptor DAT D4 receptor	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

Dopamine Receptor Signaling Pathway

Choose Selective Dopamine Receptor Inhibitors

Biological Activity

Description

Targets

Dopamine receptor ^[1]

Histamine receptor ^[1]

Adrenergic Receptor ^[1]

In vitro
In vitro	Quetiapine shows affinity for various neurotransmitter receptors including serotonin, dopamine, histamine, and adrenergic receptors and has binding characteristics at the dopamine-2 receptor similar to those of clozapine. ^[1]

In Vivo
In vivo	Quetiapine has a preclinical profile suggestive of antipsychotic activity with a reduced tendency to cause extrapyramidal symptoms (EPS) and sustained prolactin elevation. Guetiapine alters neurotensin neurotransmission and c-fos expression in limbic but not motor brain regions. Quetiapine also demonstrates clozapine-like activity in a range of behavioral and biochemical tests and may possess neuroprotective properties. ^[1] Quetiapine dose-dependently prevents schizophrenia and depression in hippocampal cell proliferation and BDNF expression caused by chronic restraint stress (CRS) in rats. Guetiapine (5 mg/kg) combined with Venlafaxine (2.5 mg/kg) increases hippocampal cell proliferation and prevents BDNF decrease in stressed rats, whereas each of the drugs exerts mild or no effects. ^[2] Guetiapine produces selective effects on cortical and limbic regions of the brain and in particular on dopaminergic neurotransmission in these regions. Guetiapine produces lower levels of putamenal DA D2r occupancy than those reported for typical APDs. Quetiapine also produces preferential occupancy of temporal cortical DA D2r, 46.9%, but does not spare occupancy of substantia nigra DA D2r. ^[3] Guetiapine attenuates the decrease in levels of brain-derived neurotrophic factor (BDNF) in the hippocampi of rats subjected to chronic-restraint stress. Guetiapine (10 mg/kg) reverses the stress-induced suppression of hippocampal neurogenesis, evidenced in the numbers of BrdU-labeled and pCREB-positive cells that are comparable to those in non-stressed rats but higher than those in the vehicle-treated rats. ^[4]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT00837343	Unknown status	Bipolar Disorder	Guangzhou Mental Hospital\|First Affiliated Hospital of Jinan University\|Second Affiliated Hospital of Guangzhou Medical University\|Guangzhou mental Hospital Attached to Guangzhou Civil Affairs Bureau	December 2008	Phase 4
NCT00838032	Unknown status	Acute Schizophrenia	Sichuan University	August 2008	Phase 4
NCT00631722	Completed	Schizophrenia	Peking University	May 2007	Not Applicable
NCT00448578	Completed	Mania\|Bipolar Disorder	AstraZeneca	August 2005	Phase 3

References

[4] Luo C, et al. Brain Res, 2005, 1063(1), 32-39.

+ Expand

Chemical Information & Solubility

Molecular Weight	883.09	Formula	C₄₆H₅₄N₆O₈S₂
CAS No.	111974-72-2	SDF	Download Quetiapine (ICI-204636) fumarate SDF
Smiles	C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 36 mg/mL ( (40.76 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
I want to know if your recommended formulation for in vivo experiments on the website is suitable for oral administration or injection?

Answer:
S1763 Quetiapine Fumarate can be dissolved in 0.5% CMC Na at 30 mg/ml as a suspension. It is fine for oral gavage.

Tags: buy Quetiapine (ICI-204636) fumarate | Quetiapine (ICI-204636) fumarate ic50 | Quetiapine (ICI-204636) fumarate price | Quetiapine (ICI-204636) fumarate cost | Quetiapine (ICI-204636) fumarate solubility dmso | Quetiapine (ICI-204636) fumarate purchase | Quetiapine (ICI-204636) fumarate manufacturer | Quetiapine (ICI-204636) fumarate research buy | Quetiapine (ICI-204636) fumarate order | Quetiapine (ICI-204636) fumarate mouse | Quetiapine (ICI-204636) fumarate chemical structure | Quetiapine (ICI-204636) fumarate mw | Quetiapine (ICI-204636) fumarate molecular weight | Quetiapine (ICI-204636) fumarate datasheet | Quetiapine (ICI-204636) fumarate supplier | Quetiapine (ICI-204636) fumarate in vitro | Quetiapine (ICI-204636) fumarate cell line | Quetiapine (ICI-204636) fumarate concentration | Quetiapine (ICI-204636) fumarate nmr

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):